Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: A report from the Children's Oncology Group

British Journal of Haematology

Volumn 166, Issue 2, 2014, Pages 254-259

  Tarlock, Katherine ^a,b   Alonzo, Todd A ^c,d   Moraleda, Pilar P ^e   Gerbing, Robert B ^c,d   Raimondi, Susana C ^d,f   Hirsch, Betsy A ^d,g   Ravindranath, Yaddanapudi ^d,h   Lange, Beverly ^d,i   Woods, William G ^d,j   Gamis, Alan S ^d,k   Meshinchi, Soheil ^a,b,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^h CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j AFLAC   (United States)

^k CHILDREN S MERCY HOSPITAL   (United States)

more..

Author keywords

Acute myeloid leukaemia; Clinical outcome; FLT3 ITD; Paediatric; T(6; 9)(p23; q34)

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CHILD; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE DUPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; INTERNAL TANDEM DUPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK;

ACUTE MYELOID LEUKAEMIA; CLINICAL OUTCOME; FLT3-ITD; PAEDIATRIC; T(6; 9)(P23; Q34);

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENES, NEOPLASM; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM PROTEINS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84903739416     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12852     Document Type: Article

References (15)

1. Bornhäuser, M., Illmer, T., Schaich, M., Soucek, S., Ehninger, G. & Thiede, C. (2007) Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood, 109, 2264-2265, author reply 2265.
2. Cooper, T.M., Franklin, J., Gerbing, R.B., Alonzo, T.A., Hurwitz, C., Raimondi, S.C., Hirsch, B., Smith, F.O., Mathew, P., Arceci, R.J., Feusner, J., Iannone, R., Lavey, R.S., Meshinchi, S. & Gamis, A.S. (2012) AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer, 118, 761-769.
3. Gamis, A.S., Alonzo, T.A., Gerbing, R.B., Aplenc, R., Sung, L., Meshinchi, S., Raimondi, S.C., Hirsch, B.A., Kahwash, S., Heerema-McKenney, A., Winter, L., Glick, K., Byron, P., Burden, L., Wallas, T., Davies, S.M. & Smith, F.O. (2010) Remission rates in childhood acute myeloid leukemia (AML) utilizing a dose-intensive induction regimen with or without gemtuzumab ozogamicin (GO): initial results from the Children's Oncology Group phase III trial, AAML0531. Blood (ASH Annual Meeting Abstracts), 116, 182.
4. Harrison, C.J., Hills, R.K., Moorman, A.V., Grimwade, D.J., Hann, I., Webb, D.K., Wheatley, K., deGraaf, S.S., van den Berg, E., Burnett, A.K. & Gibson, B.E. (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML10 and 12. Journal of Clinical Oncology, 1, 2674-2681.
5. Ishiyama, K., Takami, A., Kanda, Y., Nakao, S., Maeda, T., Naoe, T., Tanigcuhi, S., Kawa, K., Nagamura, T., Tabuchi, K., Atsuta, Y. & Sakamaki, H. (2012) Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant. Leukemia, 26, 1416-1419.
6. Kalbfleish, J.D. & Prentice, R.L. (1980) The Statistical Analysis of Failure Time Data. John Wileve & Sons, New York.
7. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
8. Lange, B.J., Gerbing, R.B., Feusner, J., Skolnik, J., Sacks, N., Smith, F.O. & Alonzo, T.A. (2005) Mortality in overweight and underweight children with acute myeloid leukemia. Journal of the American Medical Association, 293, 203-211.
9. Meshinchi, S., Woods, W.G., Stirewalt, D.L., Sweetser, D.A., Buckley, J.D., Tjoa, T.K., Bernstein, I.D. & Radich, J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 89-94.
10. Meshinchi, S., Alonzo, T.A., Stirewalt, D.L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G.J.L., Heerema, N.A., Gerbing, R., Lange, B.J. & Radich, J.P. (2006) Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 3654-3661.
11. Ravindranath, Y., Chang, M., Steuber, C.P., Becton, D., Dahl, G., Civin, C., Camitta, B., Carroll, A., Raimondi, S.C. & Weinstein, H.J. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia, 19, 2101-2116.
12. Schwartz, S., Jiji, R., Kerman, S., Meekins, J. & Cohen, M.M. (1983) Translocation (6;9)(p23;q34) in acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 10, 133-138.
13. Slovak, M.L., Gundacker, H., Bloomfield, C.D., Dewald, G., Appelbaum, F.R., Larson, R.A., Tallman, M.S., Bennett, J.M., Stirewalt, D.L., Meshinchi, S., Wilman, C.L., Ravindranath, Y., Alonzo, T.A., Carroll, A.J., Raimondi, S.C. & Heerema, N.A. (2006) A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia, 20, 1295-1297.
14. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., Ehninger, G. & Ilmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
15. Woods, W.G., Kobrinsky, N., Buckley, J.D., Lee, J.A., Sanders, J., Neudorf, S., Gold, S., Barnard, D.R., SeSwarte, J., Dusenbery, K., Kalousek, D., Arthur, D.C. & Lange, B.J. (1996) Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood, 87, 4979-4989.